三生制药抗癌新药被纳入突破性治疗品种

财中社
17 Apr

三生制药(01530)发布公告,宣布其自主研发的抗VEGF/PD-1双特异性抗体药物707注射液于2025年4月17日获得国家药品监督管理局纳入突破性治疗品种,适应症为一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌。该药物基于CLF2专利平台开发,目前在中国开展多项临床研究,其中一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌的III期临床研究已获批准。此外,707注射液正在国内...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10